anti-SARS-CoV-2 convalescent plasma / University of Chicago - LARVOL DELTA

Cross-sectional evaluation of medical reversals among National Institute of Health guideline practices implemented during the COVID-19 pandemic: how often did experts err in a time of crisis? (PubMed, BMJ Open) - "When faced with a novel pandemic, policymakers rapidly made hundreds of specific medical recommendations. More than two out of three were never robustly tested. Among practices tested in a randomised fashion, one in three was made in error. Pandemic recommendation errors were substantial. Early and coordinated efforts to initiate randomised trials, even during dire situations, may mitigate the perpetuation of ineffective practices."

Journal • Retrospective data • Critical care • Infectious Disease • Novel Coronavirus Disease

Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized with COVID-19: A Blinded Randomized Placebo-Controlled Trial. (PubMed, Chest) - "Among adults hospitalized with COVID-19, including those seronegative for anti-SARS-CoV-2 antibodies, treatment with convalescent plasma did not improve clinical outcomes."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. (PubMed, Transfusion) - "This synopsis highlights and summarizes recent key developments in TM and may be useful for educational purposes."

Journal • Review • Hematological Disorders • Pediatrics

Clinical Features and Outcomes of Hospitalized Solid Organ Transplant and Hematopoietic Stem Cell Recipients with Sars-CoV-2 Infection in the Midwestern United States: A Multi-Center Retrospective Cohort Study (ATC 2022) - "Treatments included remdesivir (58.5%), dexamethasone (54.4%), convalescent plasma (3.0%), IL-6 inhibitor (4.5%). This cohort had high rates of ICU admission (36.1%), bacterial co-infection (28.3%), rehospitalization (31.5%) and mortality (9.7%)."

Retrospective data • Cough • Fatigue • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Organ Transplantation • Transplantation

Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. (PubMed, Int Immunopharmacol) - "These approaches arebased on reduced inflammation due to inhibiting cytokine storm phenomena, immunomodulation,preventing acute respiratory distress syndrome (ARDS), viral neutralization, anddecreased viral load. This article highlights passive immunotherapy and immunomodulation approaches in managing and treating COVID-19 patients and discusses relevant clinical trials (CTs)."

Journal • Review • Acute Respiratory Distress Syndrome • Immune Modulation • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. (PubMed, ACS Cent Sci) - "While all three groups produced high titers of RBD-specific IgG, only RBD elicited a neutralizing antibody response to SARS-CoV-2 comparable to that of human convalescent plasma...Both RBD and RBD drove similarly robust CD4 and CD8 T cell responses that produced multiple Th1-type cytokines. We conclude that a multivalent surface display of spike RBD on polymersomes promotes a potent neutralizing antibody response to SARS-CoV-2, while both antigen formulations promote robust T cell immunity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Current advances in transfusion medicine 2020: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. (PubMed, Transfusion) - "This synopsis provides easy access to relevant topics and may be useful as an educational tool."

Clinical • Journal • Review • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Pediatrics

Early Convalescent Plasma for High-Risk Outpatients with Covid-19. (PubMed, N Engl J Med) - P3 | "The administration of Covid-19 convalescent plasma to high-risk outpatients within 1 week after the onset of symptoms of Covid-19 did not prevent disease progression. (SIREN-C3PO ClinicalTrials.gov number, NCT04355767.)."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

[VIRTUAL] AM21-46 Oral Abstract Session- Transfusion Medicine and Cellular Therapy Innovation (AABB 2021) - "Learning Objectives List demographic factors that impact anti-COVID-19 antibody levels in convalescent plasma donors...List proteomic markers that improve engraftment potential of fetal liver-derived hematopoietic stem cells. Discuss steps that can be taken to improve survival of biotinylated red blood cells."

Infectious Disease • Novel Coronavirus Disease

Target specific serologic analysis of COVID-19 convalescent plasma. (PubMed, PLoS One) - "No correlations between disease history and serology results were observed. The Genalyte Multiplex assay showed as good or better sensitivity to three other previously validated assays with FDA Emergency Use Authorizations."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Convalescent Plasma (clinicaltrials.gov) - P1; N=10; Completed; Sponsor: University of Chicago; Active, not recruiting ➔ Completed; Trial completion date: Dec 2021 ➔ Dec 2020

Clinical • Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

[VIRTUAL] Outcomes of Convalescent Plasma Transfusion for SARS-CoV2 Patients in the Intensive Care Unit (IDWeek 2020) - "In our patient cohort, the administration of CP did not improve laboratory markers or clinical outcomes. Some notable limitations of this study are the small sample size, and that the patients received CP late in their disease course. Further investigation is necessary to draw definitive conclusions about the utility of CP in the treatment of SARS-CoV2."

Clinical • Infectious Disease • Novel Coronavirus Disease

[VIRTUAL] Rapid Development of Convalescent Plasma Collection at a Hospital Based Blood Donation Center (AABB 2020) - "Having a pre-existing hospital-based blood collection facility significantly eased the procurement of convalescent plasma. The available literature review supports that CP can be beneficial and is safe. Implementing such trials is the need of the moment but interventions in highly regulated research systems might be required, to achieve timely approvals."

Clinical • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease

COVID-19 Convalescent Plasma (clinicaltrials.gov) - P1; N=10; Active, not recruiting; Sponsor: University of Chicago; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

COVID-19 Convalescent Plasma (clinicaltrials.gov) - P1; N=10; Recruiting; Sponsor: University of Chicago; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

COVID-19 Convalescent Plasma (clinicaltrials.gov) - P1; N=10; Not yet recruiting; Sponsor: University of Chicago

Clinical • New P1 trial